Today, Truveta and Alpine Immune Sciences, Inc. announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory...
Today we are excited to announce that we’ve expanded the de-identified data in Truveta Studio to include 28 additional social drivers of health (SDOH) attributes – such as education, income, housing stability, social support, and more – for nearly 80 million...
The United States is one of the most dangerous high-income countries in which to give birth. Nearly every negative maternal health outcome impacts women of color more than white women. This February, in honor of Heart Health Month and Black History Month, Truveta...
We’re proud to share that leaders from a number of our health system members have been named as Modern Healthcare’s 100 Most Influential People In Healthcare in 2022. This list showcases impactful healthcare leaders, nominated by their peers, as the most influential...
Last week, two members of Truveta Research — Dr. Charlotte Baker, DrPH, MPH, CPH, and Dr. Peter Smits, PhD — attended the 150th Annual Meeting of the American Public Health Association (APHA) in Boston. Dr. Peter Smits presented on Truveta Research’s...
